Promega Corporation has announced the launch of a new cellular target engagement technology at the SLAS 2026 conference. The technology is designed to enhance the identification and validation of drug targets within cells, potentially increasing the range of proteins that can be targeted by drugs.
This innovation aims to support researchers in drug discovery by providing more precise tools to study protein interactions and drug effects in a cellular environment. Promega’s new platform is expected to facilitate the development of therapies for a wider variety of diseases.
**Why this matters**
Expanding the druggable proteome—the set of proteins that can be modulated by drugs—is a key challenge in pharmaceutical research. Technologies that improve the ability to detect and measure drug-target interactions inside cells can accelerate the discovery of new treatments and improve the success rate of drug development programs.
Source: NewsData